Compare EW & VEEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EW | VEEV |
|---|---|---|
| Founded | 1958 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5B | 39.5B |
| IPO Year | 2000 | 2013 |
| Metric | EW | VEEV |
|---|---|---|
| Price | $86.24 | $224.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 27 |
| Target Price | $95.83 | ★ $299.92 |
| AVG Volume (30 Days) | ★ 3.0M | 1.6M |
| Earning Date | 02-10-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.69 |
| EPS | 2.33 | ★ 5.13 |
| Revenue | ★ $5,883,800,000.00 | $3,080,246,000.00 |
| Revenue This Year | $14.29 | $17.74 |
| Revenue Next Year | $9.68 | $12.24 |
| P/E Ratio | ★ $37.32 | $43.86 |
| Revenue Growth | 10.60 | ★ 15.96 |
| 52 Week Low | $65.94 | $201.54 |
| 52 Week High | $87.89 | $310.50 |
| Indicator | EW | VEEV |
|---|---|---|
| Relative Strength Index (RSI) | 56.14 | 32.72 |
| Support Level | $85.79 | $223.40 |
| Resistance Level | $87.44 | $226.50 |
| Average True Range (ATR) | 1.38 | 4.68 |
| MACD | 0.08 | 2.15 |
| Stochastic Oscillator | 77.46 | 50.50 |
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.